Last updated: August 17, 2026
Locoid Lipocream is a mature topical corticosteroid containing hydrocortisone butyrate 0.1%. Its commercial position depends on brand recognition, vehicle differentiation, prescribing habits, pharmacy reimbursement, and distribution rather than active patent exclusivity. Public sources do not report standalone Locoid Lipocream revenue, so its financial trajectory must be assessed through product maturity, generic competition, prescription volume, pricing, and portfolio economics.
What is Locoid Lipocream and how does it work?
Locoid Lipocream contains hydrocortisone butyrate at a concentration of 0.1%, equal to 1 mg per gram of cream. It is a topical corticosteroid indicated for corticosteroid-responsive dermatoses, including inflammatory and pruritic skin conditions such as atopic dermatitis and contact dermatitis.[1]
The product is generally categorized as a medium-potency topical corticosteroid. Its commercial differentiation comes from the Lipocream vehicle, which is designed to provide a more cosmetically acceptable and moisturizing formulation than some conventional ointments and creams.
| Product attribute |
Locoid Lipocream |
| Active ingredient |
Hydrocortisone butyrate |
| Strength |
0.1% |
| Dosage form |
Topical cream |
| Therapeutic class |
Topical corticosteroid |
| Typical potency |
Medium |
| Route |
Cutaneous |
| FDA regulatory pathway |
Prescription drug, NDA product |
| Primary uses |
Corticosteroid-responsive dermatoses |
| Main competitors |
Generic hydrocortisone butyrate cream, lotion, and ointment |
| Commercial maturity |
Long-established brand with generic competition |
The label instructs patients to apply a thin film to affected areas, generally twice daily, with treatment duration and area of use determined by the prescribing clinician.[1]
What is the FDA status of Locoid Lipocream?
Locoid Lipocream is an FDA-approved prescription product. The hydrocortisone butyrate product family originated in the U.S. market decades ago, and the relevant FDA approval history predates the current commercial market structure.[2]
The product does not benefit from meaningful remaining new-drug exclusivity. Any original approval exclusivity has expired. Current market access is therefore governed by the approved labeling, manufacturing compliance, product quality, pharmacy substitution rules, and commercial contracting.
What is the Orange Book status of Locoid Lipocream?
The FDA Orange Book is the controlling source for approved products, therapeutic-equivalence evaluations, patents, and exclusivity listings.[3] Locoid Lipocream is exposed to generic substitution because hydrocortisone butyrate cream products have been approved through abbreviated new drug applications.
The commercial implications are:
- Brand-prescribing physicians can continue to specify Locoid Lipocream.
- Pharmacies may substitute an FDA-rated therapeutically equivalent generic where state law and the prescription permit substitution.
- Payers can impose higher patient cost-sharing on the branded product.
- The brand must justify any price premium through vehicle preference, clinical familiarity, supply reliability, or formulary positioning.
No active composition-of-matter patent creates a current barrier to generic hydrocortisone butyrate cream competition. The product’s competitive protection is primarily commercial and formulation-based rather than patent-based.
What patents protect Locoid Lipocream?
Locoid Lipocream has no apparent current patent estate that provides broad exclusionary protection over hydrocortisone butyrate 0.1% cream. The active ingredient and basic topical use are long established.
| Protection category |
Current commercial significance |
| Hydrocortisone butyrate composition |
Original protection expired |
| Basic topical corticosteroid use |
No meaningful current exclusivity |
| 0.1% cream dosage form |
Generic manufacturers can compete with equivalent products |
| Lipocream vehicle |
May support brand differentiation, but does not necessarily block therapeutic equivalents |
| Method-of-use patents |
No material current barrier identified |
| Manufacturing patents |
Potentially relevant to individual suppliers, not a broad market barrier |
| Regulatory exclusivity |
Expired for the mature product |
What formulations are protected by Locoid-related intellectual property?
The Lipocream formulation may contain excipients and manufacturing parameters that distinguish the branded product from other creams. Those differences can affect texture, spreadability, absorption, cosmetic acceptability, and patient adherence.
Formulation differentiation does not automatically create market exclusivity. A generic applicant generally needs to demonstrate pharmaceutical equivalence and bioequivalence or meet the applicable FDA standards for the dosage form. It may use a different inactive-ingredient system if the finished product satisfies FDA requirements.
The likely commercial value of the Lipocream formulation is therefore defensive. It can support physician and patient preference, but it is unlikely to prevent substitution by approved generic hydrocortisone butyrate products.
When does Locoid Lipocream lose exclusivity?
Locoid Lipocream has already lost its original regulatory exclusivity and any practical composition-of-matter protection. Generic competition is established rather than an upcoming risk.
| Milestone |
Commercial effect |
| Original NDA approval |
Created initial prescription market protection |
| Expiration of original exclusivity |
Allowed ANDA competition |
| Generic hydrocortisone butyrate approvals |
Reduced brand pricing power |
| Current market phase |
Mature, substitution-driven market |
The key issue is not the date of a future patent expiry. It is the degree of ongoing generic substitution and the ability of the brand owner to retain prescriptions outside mandatory substitution channels.
Which companies compete with Locoid Lipocream?
Competition comes from both branded and generic topical corticosteroid products. The closest substitutes are generic hydrocortisone butyrate creams, while broader therapeutic competition includes other medium-potency corticosteroids.
Direct generic competition
Generic hydrocortisone butyrate products may be marketed as creams, ointments, or lotions. Manufacturers and labelers in this segment have included companies such as Taro Pharmaceuticals, Perrigo, Fougera, Prasco, and other generic suppliers, depending on product presentation and market period.
The relevant competitive dimensions are:
- FDA therapeutic-equivalence rating
- Wholesale acquisition cost
- Pharmacy availability
- Formulation consistency
- Tube sizes
- Reimbursement status
- Manufacturer supply continuity
- Prescriber and patient familiarity
Therapeutic alternatives
Locoid Lipocream also competes with:
- Hydrocortisone valerate products
- Desonide products
- Triamcinolone acetonide products
- Fluocinolone acetonide products
- Mometasone furoate products
- Nonsteroidal topical agents such as tacrolimus, pimecrolimus, and crisaborole
- Newer topical therapies for atopic dermatitis, including topical Janus kinase inhibitors
These alternatives are not exact pharmaceutical equivalents. Physicians select among them based on disease severity, body site, age, duration of treatment, steroid-sparing objectives, payer coverage, and tolerability.
How strong is the Locoid Lipocream patent estate?
The patent estate is weak as a current market-exclusion tool. The product’s core active ingredient, concentration, and therapeutic use are mature. There is no evident patent barrier comparable to the estates protecting recently launched dermatology products.
Patent-strength assessment
| Factor |
Assessment |
| Composition-of-matter protection |
Expired |
| New formulation exclusivity |
Limited practical impact |
| Method-of-use protection |
No material current barrier identified |
| Manufacturing complexity |
Low to moderate |
| Generic development difficulty |
Low to moderate |
| Substitution risk |
High |
| Brand durability |
Dependent on commercial execution |
The formulation may create manufacturing know-how or product-quality advantages. Those advantages are narrower than enforceable patent exclusivity and can be challenged through competition from approved generic products.
What generic entry risks exist for Locoid Lipocream?
Generic entry risk is high because the market already includes generic hydrocortisone butyrate products. The principal risks are sustained volume erosion, payer-driven substitution, lower net pricing, and loss of preferred pharmacy placement.
Generic launch scenarios
| Scenario |
Expected effect |
| One or two reliable generic suppliers |
Moderate price erosion and continued brand niche |
| Several active generic suppliers |
Significant price compression and lower brand volume |
| Generic supply disruption |
Temporary brand volume recovery or price stabilization |
| Formulary exclusion |
Rapid decline in reimbursed brand prescriptions |
| Consumer preference for branded vehicle |
Partial retention of cash-pay and physician-directed demand |
The brand may retain demand among patients who prefer the Lipocream texture or who have previously responded well to the product. That retention is commercially meaningful only if payers allow access at a manageable patient cost.
What is the financial trajectory for Locoid Lipocream?
Locoid Lipocream is best characterized as a mature, low-growth prescription dermatology asset. Its revenue trajectory is likely shaped by declining unit volume, net-price pressure, and occasional stabilization from brand loyalty or supply disruptions.
Standalone revenue, prescription volume, gross margin, and operating profit are not generally disclosed in public filings for the product. If the product is held within a broader dermatology portfolio or commercialized through licensing or distribution arrangements, reported financial statements may aggregate it with other brands.
Financial trajectory by market phase
| Period |
Likely financial characteristics |
| Launch and early expansion |
Brand-driven prescription growth and premium pricing |
| Pre-generic maturity |
Stable volume with established physician awareness |
| Post-generic entry |
Lower price, reduced market share, higher substitution |
| Current mature phase |
Low growth, limited pricing power, cash-flow contribution dependent on cost structure |
The economics can remain attractive despite modest revenue if manufacturing costs are low, marketing requirements are limited, and distribution is efficient. A mature topical product can generate portfolio cash flow without requiring large clinical-development spending.
Revenue exposure
Locoid Lipocream’s revenue exposure is concentrated in the U.S. prescription dermatology market and is sensitive to:
- Commercial payer formulary decisions
- Medicaid reimbursement
- Medicare Part D coverage where applicable
- Pharmacy benefit manager rebates
- Generic substitution
- Dermatology prescription trends
- Seasonal dermatitis demand
- Product availability
- Brand advertising and sampling
- Changes in the owner’s dermatology sales force
The product is unlikely to represent a major growth driver for a diversified pharmaceutical company. Its value is more consistent with a mature cash-generating brand, a portfolio add-on, or a licensing asset.
What licensing deals affect Locoid Lipocream?
Locoid has been associated with established dermatology manufacturers and brand portfolios, but public disclosures do not provide a consistent standalone accounting of product-level royalties, transfer prices, or license economics.
For a buyer or licensee, the key diligence issues are:
- Whether the counterparty controls the U.S. trademark.
- Whether the agreement covers the Lipocream formulation, other Locoid dosage forms, or the full product family.
- Whether manufacturing is internal or outsourced.
- Whether the agreement includes minimum purchase obligations.
- Whether generic versions are excluded from the licensed territory.
- Whether the brand owner controls regulatory submissions and pharmacovigilance.
- Whether the contract permits price changes, channel expansion, or private-label distribution.
Trademark and commercial rights may retain value after patent expiry, particularly where physicians recognize the product name and patients prefer the vehicle. Those rights do not eliminate generic substitution.
What patent litigation affects Locoid Lipocream?
No major current Paragraph IV litigation is associated with Locoid Lipocream as a material commercial event. The reason is structural: the product does not depend on an active patent blocking ANDA approval.
Paragraph IV litigation generally arises when an ANDA applicant challenges an unexpired patent listed in the Orange Book. For this mature topical corticosteroid product, the relevant risk is ordinary generic competition rather than a pending patent dispute.
| Litigation category |
Current relevance |
| Paragraph IV challenge |
Low apparent relevance |
| Patent infringement action |
No major current case identified |
| Trademark dispute |
Possible but not central to generic entry |
| Product liability |
Case-specific and not a market-exclusivity issue |
| Regulatory enforcement |
Dependent on manufacturing and labeling compliance |
How does Locoid Lipocream compare with newer dermatology drugs?
Locoid Lipocream has a lower scientific and regulatory risk profile than newer dermatology products, but it also has lower growth potential and weaker pricing power.
| Attribute |
Locoid Lipocream |
Newer branded dermatology therapy |
| Active patent protection |
Limited or expired |
Often substantial |
| Generic substitution |
High |
Usually low before patent expiry |
| Clinical positioning |
Established topical steroid |
May offer steroid-sparing or targeted treatment |
| Price power |
Low to moderate |
Moderate to high |
| Development risk |
Low |
High |
| Commercial growth |
Mature |
Potentially higher |
| Manufacturing barriers |
Limited |
Product-specific |
| Portfolio role |
Cash flow and channel presence |
Growth and valuation driver |
Locoid can remain relevant where clinicians need a familiar medium-potency topical steroid. It is less competitive in segments where prescribers prioritize steroid-sparing treatment, advanced atopic dermatitis therapies, or simplified treatment regimens.
What is the outlook for Locoid Lipocream?
The base-case outlook is stable to declining revenue, with the greatest pressure coming from generic substitution and reimbursement. A meaningful recovery would require a specific commercial catalyst, such as improved payer access, a differentiated distribution strategy, supply shortages among generic competitors, or successful repositioning of the vehicle.
The product has limited exposure to clinical-development failure because its safety and efficacy profile is established. Its main risks are commercial:
- Continued generic price erosion
- Loss of formulary status
- Reduced dermatology sales coverage
- Manufacturing or supply interruptions
- Declining physician preference for topical corticosteroids
- Patient migration to nonsteroidal or newer branded treatments
The asset remains suitable for a portfolio seeking established prescription revenue with limited development expense. It is less suitable for an investment thesis based on high growth, patent-protected pricing, or near-term market expansion.
Key Takeaways
- Locoid Lipocream contains hydrocortisone butyrate 0.1% and is a mature medium-potency topical corticosteroid.
- Original regulatory exclusivity and practical composition-of-matter protection have expired.
- Generic hydrocortisone butyrate competition creates high substitution and price-erosion risk.
- The Lipocream vehicle may support patient and physician preference but does not create a broad generic barrier.
- No major current Paragraph IV litigation appears to determine market access.
- Public companies generally do not disclose standalone Locoid Lipocream revenue or profit.
- The financial profile is more consistent with mature portfolio cash flow than with a growth asset.
- Future performance depends on formulary access, pharmacy distribution, brand loyalty, manufacturing reliability, and generic supply conditions.
FAQs
Is Locoid Lipocream still patent protected?
No material active patent protection appears to block generic hydrocortisone butyrate cream competition. The product’s commercial protection is primarily based on its trademark, formulation familiarity, and distribution.
Can pharmacies substitute generic hydrocortisone butyrate for Locoid Lipocream?
Substitution depends on FDA therapeutic-equivalence ratings, state pharmacy law, and the prescription’s dispense-as-written status. Where permitted, pharmacies and payers commonly favor lower-cost generic products.
Is Locoid Lipocream a high-growth pharmaceutical product?
No. It is a mature dermatology product with limited pricing power and established generic competition. Its value is more likely tied to recurring portfolio cash flow than to prescription expansion.
Does Locoid Lipocream compete with tacrolimus or crisaborole?
Yes, at the therapeutic level. Tacrolimus, crisaborole, and other nonsteroidal products may be selected when clinicians seek steroid-sparing treatment, particularly for sensitive body sites or longer-term management.
What would increase the commercial value of Locoid Lipocream?
Improved formulary coverage, reliable supply, stronger physician preference for the Lipocream vehicle, effective brand retention programs, and generic supply disruption could support revenue. None would restore the pricing power associated with active patent exclusivity.
References
-
DailyMed. (n.d.). Locoid Lipocream: Hydrocortisone butyrate cream, 0.1% prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
